Australia’s Therapeutic Goods Administration (TGA) is considering adding unique device identification (UDI) information to certificates of free sale for medical devices.
TGA issues certificates of free sale to give importing countries evidence that devices are legally available for supply in Australia. The agency issues the certificates for devices that are in the Australian Register of Therapeutic Goods (ARTG). TGA’s certificates contain information including the ARTG number, product description, GMDN code, and medical device class.
The agency is seeking feedback on whether UDI information should be included with the certificates. Australia introduced the UDI framework in March 2025 and started making compliance mandatory from 1 July 2026.
“The introduction of the Australian UDI framework provides a means of identifying medical devices at a more granular level than the ARTG ‘kind of device’,” TGA said. “This raises the question of whether providing access to UDI information alongside certificates of free sale would assist applicants or certificate recipients to identify the specific devices associated with a certificate.”
TGA is running the consultation to understand whether including UDI information would be useful to sponsors applying for certificates and to overseas regulators. The consultation is also addressing whether providing this information could create additional administrative, financial, or regulatory burdens.
The agency is considering three options. Under option one, TGA would not add UDI information to the certificate of free sale. Instead, recipients of certificates could access the information via a reference or link to the Australian UDI database. That approach would maintain the distinction between information in the ARTG and the additional details available in the database.
TGA’s second option is to allow applicants to provide UDI information in a schedule accompanying their applications. That approach would allow UDI information to accompany a certificate without becoming a standard component of every document. The third option is to make UDI information a standard part of the certificates.
The agency identified challenges that could arise if UDI information becomes a standard component of certificates. UDI information can change during the life of a medical device, resulting in certificates that no longer reflect the current device identifier. Equally, devices can have multiple identifiers. Including every identifier could make certificates or accompanying schedules significantly more complex, TGA said.
TGA is seeking feedback until 31 January. The agency wants to know which option people prefer, what information would be useful, and whether directing certificate recipients to the Australian UDI database would meet users’ needs.
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has published a question-and-answer document on clinical trial consultations for pediatric drug development.
The document features six questions from sponsors of pediatric clinical trials. In one response, PMDA clarified that sponsors can discuss modeling and simulation or pediatric extrapolation at pre-consultation and drug development pipeline meetings, depending on whether they want to cover a specific product or have a broader conversation.
Another question covers whether sponsors can discuss clinical trials in adults and children during a single formal scientific consultation. Joint discussions of adult and pediatric populations may be possible when the clinical trial designs and key issues are similar across age groups, PMDA said.
Sponsors should request a pre-consultation meeting and discuss whether the proposed questions can be addressed in a single formal scientific consultation or whether the range of topics is too broad to discuss adequately within the available time period. When trial designs or key issues differ substantially between adults and children, it may not be feasible to discuss both populations in a single scientific consultation.
The Q&A also covers substantial changes to pediatric drug development plans, how to seek scientific advice at an early stage of development, inquiries about eligibility for regulatory support schemes, and conducting pediatric clinical trials sequentially in different age groups.
The Central Drugs Standard Control Organization (CDSCO) has reminded Indian state officials of the need to add drug testing laboratories to the Sugam Labs Portal.
CDSCO asked regional officials to start onboarding labs and employees in September. As of 9 November, the agency had received Sugam onboarding requests from 16 states or union territories. Only five states had completed the onboarding process. India has 28 states and eight union territories.
The pace of the response to the initial request led CDSCO to ask regional drug controllers to expedite the onboarding process. The controllers should provide details of their officials and drug testing laboratories via email as soon as possible. CDSCO needs the information to complete the onboarding process and operationalize the Sugam portal across India.
Sugam connects CDSCO, state food and drug administrations, drug inspectors, regulatory offices, and drug testing laboratories. CDSCO designed the platform to provide an integrated digital workflow, facilitating end-to-end management of activities including sample collection, laboratory testing, result approval, report generation, and enforcement actions.
India’s National Pharmaceutical Pricing Authority (NPPA) has ordered state drug controllers to ensure compliance with a recently implemented cap on the margins of 137 oncology drugs.
NPPA capped the margins on 9 November. Days later, the authority ordered state drug controllers to strictly monitor compliance by manufacturers, dealers, hospitals, and medical institutions. NPPA submitted the request to ensure the benefits of the revised maximum prices are passed on to patients. State drug controllers have until 16 November to submit action-taken reports.
The agency has published revised price lists based on the information companies submitted up to 11 November. Manufacturers, retailers, dealers, stockists, hospitals, and medical institutions must comply with the caps and prominently display the updated price lists at their premises and on their websites.
NPPA wants people to report any violations or complaints of overcharging or drug shortages. Companies that overcharge could face penalties under the Drugs (Prices Control) Order 2013.
Press Release, NPPA Memo, More
The Drug Regulatory Authority of Pakistan (DRAP) is seeking feedback on the rules covering federal inspectors, analysts, and quality control laboratories.
DRAP’s draft rules cover the qualifications and duties of federal inspectors, explaining that people need a degree in pharmacy from a Pakistani university to hold the role. Inspectors’ duties include inspecting all premises licensed for the manufacture of therapeutic goods at least annually or as dictated by a risk-based inspection plan.
Other duties include periodic inspections of establishments licensed for the import, export, distribution, or sale of therapeutic goods. Such inspections should examine the conditions of storage, handling, and distribution, as well as associated records.
Another section of the draft covers the qualifications and activities of federal government analysts. Analysts should submit reports within 60 days of receiving a sample, and those who are unable to perform requested testing should explain why in writing.
TGA has granted another year of market exclusivity to eligible new ingredients used in listed medicines. As of 9 November, the exclusivity period is three years. TGA extended exclusivity after receiving feedback that the previous two-year exclusivity period may be too short to support product development and market entry following approval of a new ingredient. TGA Notice